Chronic graft-versus-host disease (cGVHD) is a major complication, affecting 50% to 80% of long-term survivors of allogeneic hematopoietic stem cell transplantation. Current cGVHD therapies are neither specific nor curative, and patients are typically maintained for several months to years under immunosuppressive regimens that are associated with important side effects and increased susceptibility to life-threatening infections. As a result, continued investigation into the pathology of the disease and the search for novel diagnostic and therapeutic strategies to treat cGVHD remains a high priority. We report that the cellular dynamics of various immune cell subsets are related to cGVHD onset and severity in a cohort of allogeneic hematopoi...
Defective post-transplantation thymopoiesis is associated with chronic graft-versus-host disease (GV...
Donor lymphocyte infusion (DLI) can (re-)induce durable remission in relapsing patients after alloge...
Human graft-versus-host disease (GVHD) biology beyond 3 months after hematopoietic stem cell transpl...
We analyzed lymphocyte subpopulations and cytokines 3 months after allogeneic hematopoietic stem cel...
AbstractChronic graft-versus-host disease (cGVHD) is a serious and frequent complication of allogene...
AbstractGraft-versus-host disease (GVHD) is a major transplantation complication. The purpose of thi...
Chronic graft-versus-host disease (cGVHD) is a leading cause of late morbidity and mortality followi...
AbstractThe pathophysiology of acute graft-versus-host disease (GVHD) remains poorly understood in h...
Chronic graft-versus-host disease (cGVHD) remains a major complication of allogeneic haematopoietic ...
We tested the hypothesis that changes in the phenotype of CD8+ T cells from patients with chronic gr...
Chronic graft-versus-host disease (GVHD) is the most common cause of poor long-term outcomes after a...
AbstractChronic graft-versus-host disease (cGVHD) is a major complication of allogeneic hematopoieti...
Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell tr...
AbstractTo determine the role of regulatory T lymphocytes (Tregs) in the pathogenesis of human chron...
AbstractGraft-versus-host disease (GVHD) causes significant morbidity and mortality in patients unde...
Defective post-transplantation thymopoiesis is associated with chronic graft-versus-host disease (GV...
Donor lymphocyte infusion (DLI) can (re-)induce durable remission in relapsing patients after alloge...
Human graft-versus-host disease (GVHD) biology beyond 3 months after hematopoietic stem cell transpl...
We analyzed lymphocyte subpopulations and cytokines 3 months after allogeneic hematopoietic stem cel...
AbstractChronic graft-versus-host disease (cGVHD) is a serious and frequent complication of allogene...
AbstractGraft-versus-host disease (GVHD) is a major transplantation complication. The purpose of thi...
Chronic graft-versus-host disease (cGVHD) is a leading cause of late morbidity and mortality followi...
AbstractThe pathophysiology of acute graft-versus-host disease (GVHD) remains poorly understood in h...
Chronic graft-versus-host disease (cGVHD) remains a major complication of allogeneic haematopoietic ...
We tested the hypothesis that changes in the phenotype of CD8+ T cells from patients with chronic gr...
Chronic graft-versus-host disease (GVHD) is the most common cause of poor long-term outcomes after a...
AbstractChronic graft-versus-host disease (cGVHD) is a major complication of allogeneic hematopoieti...
Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell tr...
AbstractTo determine the role of regulatory T lymphocytes (Tregs) in the pathogenesis of human chron...
AbstractGraft-versus-host disease (GVHD) causes significant morbidity and mortality in patients unde...
Defective post-transplantation thymopoiesis is associated with chronic graft-versus-host disease (GV...
Donor lymphocyte infusion (DLI) can (re-)induce durable remission in relapsing patients after alloge...
Human graft-versus-host disease (GVHD) biology beyond 3 months after hematopoietic stem cell transpl...